Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Novartis' top lawyer is taking responsibility for the controversial contract with Essential Consultants and stepping down, amid pledges by the company to polish its tarnished image.
Launch approval of Netherlands-based Kiadis Pharma's lead asset ATIR101 looks likely in Europe by early-2019 for safer, more effective bone marrow transplants. US approval will take longer.
Perrigo has got another Complete Response Letter on its generic version of Teva's ProAir, the company’s fourth to date, prompting a cut in its 2018 EPS guidance.
Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.
Danish vaccine specialist's BN-Brachyury has been granted orphan drug designation by the FDA for treating chordoma.
Sarepta is expecting the European Medicines Agency to recommend against EU approval of its Duchenne muscular dystrophy treatment eteplirsen. Persuading the agency to change its mind during the appeal will be an uphill task for the company.